A Modified and Cost-Effective HPLC Method for Determination of Plasma Concentrations of Rifampicin in Pulmonary TB Patients

Authors

  • Abida Shaheen
  • Tausif Ahmed Rajput
  • Fahad Azam

Keywords:

Tuberculosis, Rifampicin, Pharmacokinetics, High performance liquid chromatography, Accuracy, Precision, Cost effectiveness

Abstract

Objective: To evaluate the pharmacokinetics of standard doses of rifampicin (RMP) in fixed dose combination in pulmonary
tuberculosis patients by a modified high performance liquid chromatography (HPLC) method
Materials and Methods: This descriptive study was conducted after approval from Ethical Committee, Army Medical College
Rawalpindi and was funded in part by National University of Sciences and Technology (NUST), Islamabad. Twenty adult
patients with newly diagnosed pulmonary TB consented to participate in the study. RMP plasma concentrations were assayed
by a simple and sensitive HPLC method in the initial phase of pulmonary tuberculosis treatment. The method was modified
to use naproxen as an internal standard and validated according to International Conference on Hormonization (ICH) guidelines.
Results: The calibration curve of rifampicin was linear within the range of 0.781–50 μg/ml. Both intra-day and inter-day
variability and accuracy demonstrated good reproducibility at all quality control levels. The developed method was found to
be simple, precise and accurate for estimation of rifampicin in plasma. The pharmacokinetic parameters of RMP showed marked
inter-individual differences and sub-therapeutic levels.
Conclusion: Evaluation of pharmacokinetics of standard doses of rifampicin in fixed dose combination in pulmonary tuberculosis
patients by a modified high performance liquid chromatography (HPLC) method is precise, accurate and cost-effective. It may
be used for monitoring plasma RMP levels in TB patients who are slow to respond or are non-responders and have less availability
of resources.
Keywords: Tuberculosis,

References

REFERENCES:

World Health Organization. Global tuberculosis control:

WHO report 2013. Report no. WHO/HTM/TB/2013.11

Mitchison DA. The Garrod Lecture. Understanding the

chemotherapy of tuberculosis-current problems. J Antimicrob

Chemother 1992; 29: 477– 93

Panchagnula R, Sood A, Sharda N, Kau K, Kaul CL.Determination

of rifampicin and its main metabolite in plasma

and urine in presence of pyrazinamide and isoniazid

by HPLC method. J Pharm Biomed Anal 1999; 18: 101

–20

ICH Harmonized Tripartite Guideline International conference

on harmonization of technical requirements for

registration of pharmaceuticals for human use Validation

of analytical procedures: Text and methodology 2005

World Medical Association Declaration of Helsinki. Ethical

Principles for Medical Research Involving Human

Subjects. Adopted by the 18th WMA General Assembly

(1964) Helsinki, Finland and amended by the 59th WMA

General Assembly 2008, Seoul

Weber A, Opheim KE, Smith AL, Wong K. High pressure

liquid chromatographic quantitation of rifampicin and

its two major metabolites in urine and serum. Rev Infect

Dis 1983; 5: 433-9

Unsalan M, Sancar M, Bekce B, Karagoz T, Izzettin FV,

Rollas S. Therapeutic monitoring of isoniazid, pyrazinamide

and rifampicin in tuberculosis patients using LC.

Chromatographia 2005; 61:595-8

Allanson AL, Cotton MM, Tettey JN, Boyter AC. Determination

of rifampicin in human plasma and blood spots

by high performance liquid chromatography with UV

detection: a potential method for therapeutic drug monitoring.

J Pharm Biomed Anal 2007; 44: 963-9

Oswald S, Peters J, Venner M, Siegmund W. LC-MS/MS

method for the simultaneous determination of clarithromycin,

rifampicin and their main metabolites in horse

plasma, epithelial lining fluid and broncho-alveolar cells.

J Pharm Biomed Anal 2011; 55:194-201

Ratti B, Parenti R R, Toselli A, Zerilli L F. Quantitative

assay of rifampicin and its metabolite 25-desacetyl rifampicin

in human plasma by reverse-phase high performance

liquid chromatography. J Chromatogr 1981; 225:

-31

Calleri E ,De Lorenzi E, Furlanetto S , Massolini G, Caccialanza

G Validation of a RP-LC method for the simultaneous

determination of isoniazid, pyrazinamide and

rifampicin in a pharmaceutical formulation. 2002; 29:10

-96

Tarczak MT, Flieger J, Szumilo H. High-performance

liquid-chromatographicn determination of rifampicin in

complex pharmaceutical Preparation and in serum mycobacterium

Tuberculosis infected patients. Acta Poloniae

Pharmaceutica-Drug Research 2005; 62: 251-6

JS, , S AR, MS. Development and Validation of Liquid

Chromatography-Mass Spectrometry Method for the Estimation

of Rifampicin in Plasma Indian J Pharm Sci 2

; 73: 558–63

Shaheen A, Najmi MH, Saeed W, Farooqi Z. Pharmacokinetics

of standard dose regimens of rifampicin in patients

with pulmonary tuberculosis in Pakistan. Scandinavian

Journal of Infectious Diseases 2012; 44: 459-64

Peloquin CA. Using therapeutic drug monitoring to dose

the antimycobacterial drugs. Clin Chest Med 1997; 18:

–87

Kimerling ME, Phillips P, Patterson P, Hall M, Robinson

CA, Dunlap NE. Low serum antimycobacterial drug levels

in non-HIV infected tuberculosis patients. Chest 1

; 113: 1178–83

Zhang JN, Liu XG, Zhu M, Chiu FC, Li RC. Assessment

of presystemic factors on the oral bioavailability of rifampicin

following multiple dosing. J Chemother 1998;10:

– 9

Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain

F, Roy TM. Utility of rifampin blood levels in the

treatment and follow-up of active pulmonary tuberculosis

in patients who were slow to respond to routine directly

observed therapy. Chest 2001; 120: 1520–4

Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron

H, Pillai G et al. Population pharmacokinetics of

rifampin in pulmonary tuberculosis patients, including

a semi mechanistic model to describe variable absorption.

Antimicrob Agents Chemother 2008; 52: 2138–48

Ellard GA. The evaluation of rifampicin bioavailabilities

of fixed-dose combinations of antituberculosis drugs:

Procedures for ensuring laboratory proficiency. Int J Tubercle

Lung Dis 1999; 3:322-4

van Crevel R, Alisjahbana B, de Lange WC, Borst F, Danusantoso

H, van der Meer JW et al. Low plasma concentrations

of rifampicin in tuberculosis patients in Indonesia.

Int J Tuberc Lung Dis 2002; 6: 497–502

Sankar R, Sharda N, Singh S. Behaviour of decomposition

of rifampicin in the presence of isoniazid in the pH

range 1-3. Drug Dev Ind Pharm 2003; 29: 733–8

Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic

aspects of variable bioavailability of rifampicin.

Int J Pharm 2004; 271: 1–4

McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith

P. Determinants of rifampin, isoniazid, pyrazinamide

and ethambutol pharmacokinetics in a cohort of tuberculosis

patients. Antimicrob Agents Chemother 2006;

: 1170–7

Tappero J W, Bradford W Z. Agerton T B, Hopewell P,

Reingold A.L, Lockman S, et al . Serum concentration

of antimycobacterial drugs in patients with pulmonary

tuberculosis in Botswana. Clin Infect Dis 2005;41:461-9

Downloads

Published

2015-09-03

How to Cite

Shaheen, A. ., Rajput, T. A. ., & Azam, F. . (2015). A Modified and Cost-Effective HPLC Method for Determination of Plasma Concentrations of Rifampicin in Pulmonary TB Patients. Journal of Bahria University Medical and Dental College, 5(3), 121–126. Retrieved from https://jbumdc.bahria.edu.pk/index.php/ojs/article/view/125

Issue

Vol. 5 No. 3 (2015): Volume 5 Issue 3

Section

Original Articles

License

Copyright (c) 2015 Abida Shaheen, Tausif Ahmed Rajput, Fahad Azam

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0